Remove 2015 Remove FDA Remove Side effects
article thumbnail

Thursday pharma headlines

World of DTC Marketing

million, his first big raise since 2015, thanks to incentive pay that jumped by about $1.2 million in 2020, more than double the number in 2015, according to health data company IQVIA. Food and Drug Administration (FDA) is meant to help patients and warn of potential drug side effects but a Vice report indicates something more.

Pharma 180
article thumbnail

FDA rejects Spectrum’s lung cancer drug poziotinib

pharmaphorum

The FDA has issued a complete response letter (CRL) to Spectrum Pharma for poziotinib, its pan HER2 inhibitor for a form of lung cancer, according to South Korea’s Hanmi Pharma, which originally developed the drug. Spectrum licensed worldwide rights to poziotinib – excluding Korea and China – from Hanmi in back in 2015.

FDA 98
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Clinical trials authorised for 3D-printed ulcerative colitis drug

European Pharmaceutical Review

a China-based pharma company has announced it has received clearance for its Investigational New Drug (IND) application from the US Food and Drug Administration (FDA) to initiate clinical studies of T21, a 3D-printed medicine that can target specific segments in the colon to more safely deliver oral ulcerative colitis (UC) drugs.

article thumbnail

FDA raises alarm about weight-gain supplement apetamin

Pharmaceutical Technology

The sale of an illegally imported supplement being marketed as a weight-gain enhancer has been associated with cases of dizziness, cognitive impairment, and sedation, according to the US Food and Drug Administration (FDA). In this case, the woman had taken apetamin in the form of cyproheptadine, lysine, and vitamin syrup.

article thumbnail

Ionis antithrombotic with reduced bleed risk clears phase 2b study

pharmaphorum

Patients with end-stage renal disease (ESRD) who are on dialysis often need to be treated with anticoagulants to prevent blood clots, but as a result, can experience bleeding side effects. Now, Ionis and Bayer think they have a new drug that could sidestep that risk. Bayer hasn’t yet revealed whether the results were positive.

article thumbnail

The evolving role of social media in healthcare

pharmaphorum

Back in 2015, the influencer-of-influencers, Kim Kardashian, was slammed for failing to mention the potential side effects of an anti-nausea drug, leading to the US FDA getting involved. Despite the slap on the wrist, the campaign was highly effective and there is no sign of this approach going away.

Media 103
article thumbnail

Female sexual interest drug reaches tipping point with Phase III plans

Pharmaceutical Technology

The company plans to submit a request for advice from the FDA at the end of this year or the start of 2023, he adds. In 2015, the FDA approved Sprout Pharmaceuticals’s Addyi, also known under the generic name flibanserin, for use by pre-menopausal women with hypoactive sexual desire disorder (HSDD).